Peptides having skin condition-improving activity and uses thereof

Abstract

The present application relates to a peptide having skin condition-improving activity and use thereof, and provides a peptide consisting of the amino acid sequence of SEQ ID NO: 1 and a cosmetic composition for skin condition improvement including the peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an effective ingredient.

Description

TECHNICAL FIELD

[0001] The present application relates to a peptide having skin condition-improving activity and use thereof. BACKGROUND

[0002] Human skin is continuously changing, and the most representative of these changes is a decrease in skin function and a decrease in visual beauty due to aging. Aging causes wrinkles in the skin, and as representative factors in the formation of wrinkles, exposure to ultraviolet rays and a decrease in collagen biosynthesis can be cited. Skin aging is roughly divided into intrinsic aging due to genetic factors and extrinsic aging due to external environmental factors such as sunlight. Among them, for extrinsic aging, it is known that aging can be prevented, treated, or delayed by removing active oxygen, proliferating fibroblasts, and promoting collagen biosynthesis, etc.

[0003] Collagen, which is a major component of the extracellular matrix, is a major matrix protein produced in fibroblasts in the skin. Collagen forms a large part of organic matter in the skin, tendons, bones, and teeth, and the content is high in bones and the skin (dermis), in particular. Such collagen decreases with age and photoaging due to ultraviolet irradiation, which is known to be closely related to the formation of wrinkles in the skin. Also, collagen plays an important role in wound treatment, and promotes collagen synthesis in damaged epithelium, thereby enabling rapid and complete recovery of wounds. Also, it has been reported that as the biosynthesis of collagen is promoted and the density of the basal layer or the like is increased, the concentration of melanin per unit skin density decreases, and thus a skin whitening effect can be expected.

[0004] In this technical background, various studies for improving the skin condition by promoting collagen biosynthesis, proliferating fibroblasts, etc., and increasing activity mechanisms are currently being conducted (Korean Registered Patent No. 10-1813629), but are still not perfect. SUMMARY

[0005] PROBLEM TO BE SOLVED BY THE INVENTION

[0006] In one aspect, there is provided a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0007] In another aspect, there is provided a cosmetic composition for skin condition improvement, including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an effective ingredient.

[0008] Other objects and advantages of the present application will become more apparent from the following detailed description when read in conjunction with the accompanying drawings and claims. As long as what is not described in the present specification is sufficiently recognized and inferred by those skilled in the art or those skilled in similar technical fields, the relevant description thereof is omitted.

[0009]

Technical Solution

[0010] Various explanations and embodiments disclosed in the present application can also be applied to various other explanations and embodiments. That is, all combinations of various elements disclosed in the present application belong to the scope of the present application. Also, it cannot be determined that the scope of the present application is limited to the specific recitations described below.

[0011] In one aspect, there is provided a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0012] The term "peptide" used in the present specification can mean a linear molecule formed by amino acid residues binding to each other through a peptide bond. The peptide can be prepared by a chemical synthesis method well known in the art, particularly, a solid phase synthesis technique or a liquid phase synthesis technique (US Registered Patent No. 5,516,891). As a result of efforts to develop a peptide having a biologically effective activity, the present inventors identified a peptide consisting of the amino acid sequence of SEQ ID NO: 1. Here, the biologically effective activity can mean selected from (a) promoting proliferation of fibroblasts or keratinocytes; (b) increasing expression of collagen type I (Col1a1), fibronectin, or elastin as a constituent factor of extracellular matrix; (c) increasing expression of skin barrier factors, i.e., sirtuin-1 (SIRT-1) or aquaporin-3 (AQP3). Accordingly, the peptide can be used for skin state improvement or antioxidant.

[0013] In the peptide, in order to obtain chemical stability, enhanced pharmacological properties (half-life, absorbability, potency, efficacy, etc.), altered specificity (e.g., a wide range of biological activity), reduced antigenicity, a protecting group can be bound at the N- or C-terminus of the terminal end of the peptide. In one embodiment, the N-terminus of the peptide can be bound with any one protecting group selected from the group consisting of an acetyl group, a fluorenylmethoxycarbonyl group, a formyl group, a palmitoyl group, a myristyl group, a stearyl group, a butoxycarbonyl group, an allyloxycarbonyl group, and a polyethylene glycol (PEG); and / or the C-terminus of the peptide can be bound with any one protecting group selected from the group consisting of an amino group (-NH2), a tertiary alkyl group, and a hydrazino group (-NHNH2). Also, the peptide can optionally further include a targeting sequence, a tag, a labeled residue, an amino acid sequence prepared for a specific purpose of increasing half-life or peptide stability.

[0014] The term "stability" used in the present specification can mean not only the in vivo stability of the peptide protected from the attack of in vivo proteolytic enzymes, but also storage stability (e.g., room temperature storage stability).

[0015] Another aspect provides a cosmetic composition for skin condition improvement, including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an effective ingredient.

[0016] Among the terms or elements mentioned in the description of the peptide, the same as what has been mentioned is as described above.

[0017] The term "improvement" used in the present specification can mean all actions that at least alleviate a parameter such as the degree of symptoms associated with the alleviation or treatment of a condition.

[0018] The term "skin condition improvement" used in the present specification can mean a process or an effect of treating, alleviating, or alleviating skin damage due to skin endogenous factors or skin exogenous factors, etc., and can be interpreted as, for example, wrinkle improvement, skin elasticity improvement, wound recovery, skin barrier strengthening, or skin aging inhibition, but is not limited thereto.

[0019] Herein, "wrinkle improvement", "skin elasticity improvement", and "wound recovery" can refer to all effects of increasing the total amount of extracellular matrix factors, including promotion of collagen synthesis, etc. Also, "skin barrier strengthening" can refer to strengthening the original function of the skin, i.e., preventing the leakage of moisture and nutrient components in the skin to the outside and preventing the invasion of harmful substances such as bacteria or viruses into the skin. Also, "skin aging inhibition" can refer to inhibition of wrinkles, skin sagging, reduction in elasticity, and the like, which are reductions in skin function. At this time, the skin aging can be photoaging, e.g., skin aging due to ultraviolet rays.

[0020] The existing functional peptides have a disadvantage in that, even though they have effective biological activity, they cannot be effectively introduced into target tissues or cells due to the size of the peptides themselves, or are eliminated from the body in a short time due to a short half-life. In contrast, the cosmetic composition according to an embodiment includes a peptide consisting of 10 or less amino acids as an effective ingredient, and thus, the skin permeation rate or the like of the effective ingredient is very excellent, e.g., when applied topically to the skin, it can effectively improve the skin condition.

[0021] According to an embodiment, it is possible to promote the proliferation of fibroblasts and keratinocytes and to enhance the synthesis of extracellular matrix constituting factors and skin barrier factors. Thus, the peptide can be used as an effective ingredient of a cosmetic composition for skin condition improvement.

[0022] The cosmetic composition can include a cosmetically effective amount of the peptide; and / or a cosmetically acceptable carrier, but is not limited thereto.

[0023] The term "cosmetically effective amount" used in the present specification refers to an amount sufficient to achieve the skin condition improvement efficacy of the cosmetic composition.

[0024] The weight ratio between the peptide and the cosmetically acceptable carrier can be, for example, 500:1 to 1:500, for example, the weight ratio can be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0025] The cosmetic composition can be prepared in any dosage form generally prepared in the art, for example, can be prepared in a solution, a suspension, an emulsion, a dough, a gel, a skin cream, a skin lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powder foundation, a liquid foundation, a wax foundation, and a spray, etc., but is not limited thereto. For example, the cosmetic composition can be prepared in a softening toner, a nourishing toner, a nourishing cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing bubble, a cleansing water, a pack, a spray, or a powder dosage form.

[0026] In the case where the dosage form of the cosmetic composition is a dough, a skin cream, or a gel, an animal oil, a vegetable oil, a wax, a paraffin, a starch, a tragacanth gum, a cellulose derivative, a polyethylene glycol, a silicon, a bentonite, a silicon dioxide, a talc, or a zinc oxide, etc. can be used as a carrier ingredient.

[0027] In the case where the dosage form of the cosmetic composition is a foundation or a spray, a lactose, a talc, a silicon dioxide, an aluminum hydroxide, a calcium silicate, or a polyamide powder can be used as a carrier ingredient, and, for example, in the case of a spray, a propellant such as a chlorofluorocarbon, a propane / butane, or a dimethyl ether can be further included.

[0028] In the case where the dosage form of the cosmetic composition is a solution or an emulsion, a solvent, a solubilizer, or an emulsifier can be used as a carrier ingredient, and, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, a glycerin aliphatic ester, a polyethylene glycol, or a sorbitan fatty acid ester can be included.

[0029] In the case where the dosage form of the cosmetic composition is a suspension, a liquid phase diluent such as water, ethanol, or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, a polyoxyethylene sorbitol ester, and a polyoxyethylene sorbitol ester, microcrystalline cellulose, methyl aluminum hydroxide, bentonite, agar, or tragacanth gum, etc. can be used.

[0030] In the case where the dosage form of the cosmetic composition is a surfactant-containing cleanser, a fatty alcohol sulfate, a fatty alcohol ether sulfate, a sulfosuccinic acid monoester, a hydroxyethyl sulfonate, an imidazoline derivative, a methyl taurate, a sarcosinate, a fatty acid amide ether sulfate, an alkyl amide betaine, a fatty alcohol, a fatty acid glyceride, a fatty acid diethanolamide, a vegetable oil, a lanolin derivative, or an ethoxylated glycerin fatty acid ester, etc. can be used as a carrier ingredient.

[0031] The peptide can be included in a nanobody or nanoparticle to further improve the skin penetration problem or the stability problem. For example, the nanobody can be prepared using lecithin as a raw material with a microfluidizer, and can be included in a lecithin particle. As a method of preparing the nanobody, any publicly known method can be used. The size of the nanobody particle is preferably 30 to 200 nm. In the case where the size of the nanobody particle is less than 30 nm, the skin penetration can be very fast to cause a skin side effect to occur, and in the case where the size of the nanobody particle is greater than 200 nm, it can be difficult to penetrate into the skin to make it difficult to obtain the use effect of the nanobody.

[0032] In addition to the peptide as an active ingredient and the carrier ingredient, the ingredients included in the cosmetic composition include conventional ingredients for a cosmetic composition, for example, can include an antioxidant, a stabilizer, a solubilizer, a vitamin, a pigment, and a fragrance, and the like conventional auxiliary agents.

[0033] The content of the peptide as the active ingredient included in the cosmetic composition can be appropriately and non-limitingly selected depending on the product form, the desired use, and the like, for example, can be added in an amount of 0.01 to 15% by weight based on the total weight of the cosmetic composition. Also, for example, the cosmetic composition can include 1.0 to 3.0% by weight, preferably 2.0 to 3.0% by weight of the peptide based on the total weight.

[0034] Another aspect provides a method of improving the skin state, including the step of applying a cosmetic composition including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient to the skin of an individual; a use of the peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of a composition for improving the skin state.

[0035] Among the terms or elements mentioned in the description regarding the cosmetic composition, the same as what has been mentioned is as described above.

[0036] The term "individual" used in the present specification means a subject in need of improvement of the skin state, and more specifically, means a human or a non-human primate, a mouse, a dog, a cat, a horse, a cow, and the like mammal.

[0037] The terms "application", "administration", and "applying" used in the present specification can be used interchangeably, and can mean at least partially localizing the composition according to an embodiment on a desired site, or disposing the composition according to an embodiment in an individual through an administration route.

[0038] Another aspect provides an antioxidant composition including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0039] Among the terms or elements mentioned in the description of the peptide, the same as those already mentioned are as described above.

[0040] The antioxidant composition can be in the form of a pharmaceutical composition, a non- pharmaceutical composition, or a cosmetic composition, and as an example, the composition can be used as a cosmetic composition for skin condition improvement, or a pharmaceutical composition for improving or treating a skin damage-related disease state.

[0041] According to an embodiment, it is indicated that the peptide is capable of restoring the reduced activity of fibroblasts or keratinocytes and enhancing the antioxidant effect thereof. Thus, the peptide can be used as an effective ingredient of an antioxidant composition.

[0042] As an example, the antioxidant composition can be provided in the form of a pharmaceutical composition. The pharmaceutical composition can include a pharmaceutically effective amount of the peptide; and / or a pharmaceutically acceptable carrier, but is not limited thereto.

[0043] The term "pharmaceutically effective amount" used in the present specification can mean an amount of the pharmaceutical composition sufficient to achieve a prophylactic or therapeutic effect on a skin damage-related disease.

[0044] The pharmaceutically acceptable carrier is generally used in preparation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, sugar syrup, methyl cellulose, glycerol, hydroxybenzoate, hydroxypropyl benzoate, talc, magnesium stearate, and mineral oil, but is not limited thereto. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th edition, 1995).

[0045] The weight ratio between the peptide and the pharmaceutically acceptable carrier can be, for example, 500:1 to 1:500, and as an example, the weight ratio can be 450:1 to 1:450, 400:1 to 1:400, 350:1 to 1:350, 300:1 to 1:300, 250:1 to 1:250, 200:1 to 1:200, 150:1 to 1:150, 100:1 to 1:100, 80:1 to 1:80, 60:1 to 1:60, 40:1 to 1:40, 20:1 to 1:20, 10:1 to 1:10, 8:1 to 1:8, 6:1 to 1:6, 4:1 to 1:4, or 2:1 to 1:2, but is not limited thereto.

[0046] The pharmaceutical composition can further include, but is not limited to, a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, etc., in addition to the ingredients.

[0047] The pharmaceutical composition can be administered by enteral or parenteral, preferably by parenteral administration. For parenteral administration, it can be administered by intramuscular injection, intravenous injection, subcutaneous injection, intraperitoneal injection, topical administration, transdermal administration, etc., but is not limited thereto.

[0048] The administration amount of the pharmaceutical composition can be 0.0001 to 1000 μg (microgram), 0.001 to 1000 μg, 0.01 to 1000 μg, 0.1 to 1000 μg, or 1.0 to 1000 μg per day, but is not limited thereto, and can be prescribed differently according to the formulation method, administration method, age, body weight, sex, condition, diet, administration time, administration route, excretion rate, and reaction sensitivity of the patient, etc.

[0049] The pharmaceutical composition can be prepared in a unit capacity form using a pharmaceutically acceptable carrier and / or excipient according to a method easily performed by one of ordinary skill in the art to which the present application pertains, or can be prepared by being injected into a multi-capacity container.

[0050] The dosage form can be in the form of a solution, a suspension, or an emulsion in an oily or aqueous solvent, or can have the form of an extractant, a powder, a granule, a tablet, or a capsule, and can further include a powder and / or a stabilizer.

[0051] Another aspect provides a food composition for improving skin condition, including a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an effective ingredient.

[0052] Among the terms or elements mentioned in the description of the peptide, the same as that which has been mentioned is as described above.

[0053] The content of the peptide included as the effective ingredient in the food composition can be appropriately and non-limitingly selected according to the form of food, desired use, etc., and, for example, can be added at 0.01 to 15% by weight based on the total weight of food. For example, for a health beverage composition, it can be added at a ratio of 0.02 to 10 g, preferably 0.3 to 1 g, based on 100 ml.

[0054]

Advantageous Effects

[0055] By the peptide according to an aspect, proliferation of fibroblast and keratinocyte can be promoted and synthesis of extracellular matrix constituent factor and skin barrier factor can be enhanced, and thus it can be applied to skin state improvement including wrinkle improvement, skin elasticity improvement, wound recovery, skin barrier reinforcement, or skin aging inhibition, etc.

[0056] Thus, the peptide according to an aspect can be used as an effective ingredient of a composition for skin state improvement. BRIEF DESCRIPTION OF DRAWINGS

[0057] Figure 1 shows the results of confirming the level of cell proliferation after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to skin cells, wherein, Figure 1 A of FIG. 1 shows the results of changes in the survival rate of NIH3T3 cells, Figure 1 B of FIG. 1 shows the results of changes in the survival rate of HaCaT cells.

[0058] Figure 2 shows the results of confirming the increase in expression of extracellular matrix constituent factors, i.e., collagen type I (Col1a1), fibronectin, and elastin, after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells.

[0059] Figure 3 shows the results of quantitatively evaluating the expression level of extracellular matrix constituent factors after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to NIH3T3 cells, wherein, Figure 3 A of FIG. 2 shows the results of confirming the expression level of Col1a1, Figure 3 B of FIG. 2 shows the results of confirming the expression level of fibronectin, Figure 3 C of FIG. 2 shows the results of confirming the expression level of elastin.

[0060] Figure 4 shows the results of confirming the increase in expression of skin barrier factors, i.e., sirtuin 1 (SIRT-1) and aquaporin 3 (AQP3), after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells.

[0061] Figure 5 shows the results of quantitatively evaluating the expression level of skin barrier factors after adding the peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells, wherein, Figure 5 A of FIG. 3 shows the results of confirming the expression level of SIRT-1, Figure 5 B of FIG. 3 shows the results of confirming the expression level of AQP3.

[0062] Figure 6Results showing that the change in the level of active oxygen increased by ultraviolet rays was quantitatively confirmed after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells.

[0063] Figure 7 Results showing that the change in the level of active oxygen increased by ultraviolet rays was quantitatively confirmed after adding a peptide consisting of the amino acid sequence of SEQ ID NO: 1 to HaCaT cells.

DETAILED DESCRIPTION

[0064] Hereinafter, the present application will be described in more detail by examples. However, these examples are only for illustratively describing the present application, and the scope of the present application is not limited to these examples.

[0065]

Example 1: Synthesis of Peptide

[0066] The peptide having the amino acid sequence of SEQ ID NO: 1 described in Table 1 below was synthesized using an automatic peptide synthesizer (Milligen 9050, Millipore, USA), and the synthesized peptide was purified and isolated using a C18 reverse phase high performance liquid chromatograph (HPLC) (Waters Associates, USA). ACQUITY UPLC BEH300 C18 (2.1 mm x 100 mm, 1.7 μm, Waters Co, USA) was used as a column.

[0067]

Table 1

[0068] SEQ ID NO Sequence (N-terminal→C-terminal) 1 DGWNY

[0069]

Example 2: Confirmation of Proliferation-Promoting Effect on Skin Cells

[0070] This example aims to confirm the effect of the peptide according to an embodiment on the proliferation of skin cells by evaluating the change in the survival rate of mouse fibroblast cells, i.e., NIH3T3 cells, or human keratinocyte cells, i.e., HaCaT cells.

[0071] Specifically, NIH3T3 cells or HaCaT cells were seeded at 5 x 10 3Cells were seeded at a density of 1 cell / well in a 96-well plate and then cultured for 24 hours. Then, the cells were washed once with serum-free DMEM media, and a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM in 200 μL of the serum-free DMEM media and cultured in a CO2 incubator at 37°C for 72 hours. Then, after washing the culture twice with PBS, an MTT (Sigma, Cat. No: M2003, USA) solution was aliquoted at 0.5 mg / mL per well. Then, after shielding from light, the culture was incubated in a CO2 incubator at 37°C for 4 hours. Then, the absorbance at 540 nm was measured. In this example, the control group was an untreated group, and a group to which an insulin-like growth factor (IGF) was added was used as a positive control group.

[0072] As a result, it was confirmed that the proliferation of fibroblasts and keratinocytes was promoted by the peptide consisting of the amino acid sequence of SEQ ID NO: 1, as shown in Table 1. Figure 1

[0073]

Example 3: Confirmation of wrinkle improvement and elasticity enhancement effects

[0074] This example aims to confirm the effects of the peptide according to an embodiment on endogenous skin aging improvement including wrinkle improvement and elasticity enhancement, etc., by evaluating the expression levels of collagen type I (Col1a1), fibronectin, or elastin, which are known as dermal components.

[0075] Specifically, NIH3T3 cells were seeded at a density of 3 x 10 5 Cells were seeded at a density of 1 cell / well in a 6-well plate and then cultured for 24 hours. Then, after washing the cells once with serum-free DMEM media, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM in the 1 mL of the culture medium and cultured in a CO2 incubator at 37°C for 24 hours. Then, after washing the culture twice with PBS, easy blue (iNtRON, Korea) was used to isolate ribonucleic acid (RNA) from the culture. 1 μg of the isolated RNA was subjected to reverse transcription using an RT kit (Enzynomics, Korea) to synthesize each complementary deoxyribonucleic acid (cDNA). Then, a polymerase chain reaction (PCR) was performed using the cDNA and Col1a1, fibronectin, and elastin primers. The control group was an untreated group, and a group to which TGF-β1 was added was used as a positive control group, and the nucleotide sequences of the primers used in this example are as follows in Table 2.​

[0076] Table 2

[0077]

[0078] As a result, it was confirmed that... Figure 2 and 3 As shown, the peptide, composed of the amino acid sequence of SEQ ID NO: 1, increased the expression of extracellular matrix constituents, namely Colla1, fibronectin, and elastin. These results indicate that the peptide according to one embodiment contributes to the improvement of endogenous skin aging, including wrinkle reduction and increased elasticity, by increasing extracellular matrix constituents.

[0079] [Example 4: Confirmation of Skin Barrier Strengthening Effect]

[0080] This embodiment aims to confirm the effect of a peptide according to one embodiment on skin barrier strengthening by evaluating the expression levels of silencing regulatory protein 1 (SIRT-1) or aquaporin 3 (AQP3).

[0081] Specifically, HaCaT cells were prepared at a rate of 3 × 10⁻⁶. 5 Cells were seeded at a density of 6-well plates and cultured for 24 hours. After washing the cells once with serum-free DMEM media, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM into 1 mL of the medium, and the culture was incubated at 37°C in a CO2 incubator for 24 hours. The culture was then washed twice with PBS, and ribonucleic acid (RNA) was isolated from the culture using easy blue (iNtRON, Korea). Complementary deoxyribonucleic acid (cDNA) was synthesized from 1 μg of the isolated RNA using an RT kit (Enzynomics, Korea). Polymerase chain reaction (PCR) was then performed using the cDNA and primers for silencing regulatory protein-1 and aquaporin-3. The control group was untreated, and a group supplemented with EGF (EGF) served as a positive control. The nucleotide sequences of the primers used in this embodiment are shown in Table 3 below.

[0082] Table 3

[0083]

[0084] As a result, it was confirmed that... Figure 4 and Figure 5As shown, the expression of SIRT-1 and AQP3, which are skin barrier factors, was increased by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. From the results, it was known that the peptide according to an embodiment contributes to skin barrier reinforcement and skin anti-aging by increasing skin barrier factors.

[0085] Example 5: Confirmation of reducing effect on active oxygen increased by ultraviolet rays

[0086] This example aims to confirm the influence of the peptide according to an embodiment on the antioxidant effect in skin cells that have been damaged by evaluating the change in the level of active oxygen in skin cells due to the irradiation of ultraviolet rays.

[0087] Specifically, NIH3T3 cells or HaCaT cells were seeded at a density of 5 x 10 5 cells / well in a 6-well plate and then cultured for 24 hours. Then, after washing the cells once with serum-free medium (serum-free DMEM medium), a peptide consisting of the amino acid sequence of SEQ ID NO: 1 was aliquoted at 50 μM or 100 μM in 1 mL of the medium and cultured in a CO2 incubator at 37°C for 1 hour. Then, after moving the culture to an e-tube, it was mixed with 1 mL of PBS to be aliquoted in a well plate. Then, the NIH3T3 cells were irradiated with ultraviolet rays at 8 J / cm 2 and the HaCaT cells were irradiated with ultraviolet rays at 15 mJ / cm 2 . Then, the PBS in the well plate was removed, and the medium to which the peptide was aliquoted was added at 900 μL, and cultured in a CO2 incubator at 37°C for 24 hours. Then, the culture was treated with 2',7'-dichlorofluorescin diacetate (DCFH-DA), wrapped with foil, and cultured in a CO2 incubator at 37°C for 30 minutes. Then, after washing twice with PBS, 500 μL of 1 x trypsin / ethylenediaminetetraacetic acid (EDTA) was used to obtain cells, and then centrifuged. The centrifuged cells were washed with PBS, and the fluorescence value was measured using flow cytometry (FACS, BD, USA). In this example, the control group was the untreated group, the comparison group (NC) was the group that was only irradiated with ultraviolet rays, and the group to which 50 μM of Trolox was added (Trolox) was used as a positive control group.

[0088] As a result, it was confirmed that, as Figure 6 and 7As shown, the increase in the level of reactive oxygen species in fibroblasts and keratinocytes due to irradiation of ultraviolet rays was reduced by the peptide consisting of the amino acid sequence of SEQ ID NO: 1. From the results, it was known that the peptide according to an embodiment is helpful to the antioxidant effect of skin cells induced by ultraviolet rays.

[0089] [Formulation Example 1: Preparation of Peptide Nanosphere]

[0090] The peptide of Example 1, 50 mg, was dissolved by stirring well using distilled water, 500 ml. After mixing the complex solution with lecithin, 5 g, sodium oleate, 0.3 ml, ethanol, 50 ml, and a small amount of oil phase, the amount was adjusted to 1 L using distilled water, and then emulsified at high pressure using a high-pressure microfluidizer to prepare a peptide nanosphere having a size of about 100 nm.

[0091] [Formulation Example 2: Softening Toner]

[0092] A softening toner including the peptide according to an embodiment and having the following composition was prepared in a manner known in the art.

[0093] [Table 4]

[0094] Ingredient Content (wt%) Peptide 1.0 1,3-Butylene glycol 6 Glycerin 4 Polyethylene glycol 1500 1 Sodium hyaluronate 1 Polysorbate 20 0.5 Ethanol 8 Benzophenone-9 0.05 Preservative, colorant q.s. Fragrance q.s. Purified water q.s. Total 100

[0095] [Formulation Example 3: Nutrition Cream]

[0096] A nutrition cream including the peptide according to an embodiment and having the following composition was prepared in a manner known in the art.

[0097] [Table 5]

[0098]

[0099]

[0100] [Formulation Example 4: Nutrition Toner]

[0101] A nutrition toner including the peptide according to an embodiment and having the following composition was prepared in a manner known in the art.

[0102] [Table 6]

[0103] Ingredient Content (wt%) Peptide 3.0 1,3-Butylene glycol 4 Glycerin 4 Cetostearyl alcohol 0.8 Glyceryl stearate 1 Triethanolamine 0.13 Tocopheryl acetate 0.3 Liquid paraffin 5 Squalene 3 Oil 2 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Carboxyvinyl polymer 1 Preservative, colorant q.s. Fragrance q.s. Purified water q.s. Total 100

[0104] [Formulation Example 5: Serum]

[0105] A serum including the peptide according to an embodiment and having the following composition was prepared in a manner known in the art.

[0106] [Table 7]

[0107]

[0108]

[0109] The description of the application only serves to provide examples, and those of ordinary skill in the art should understand that the application can be easily modified into other specific forms without changing the technical idea or essential features of the application. Therefore, the above-described embodiments should be understood in an exemplary rather than limiting sense.

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. The peptide according to claim 1, wherein, The N-terminus of the peptide is bound to any one of the protecting groups selected from the group consisting of acetyl, palmitoyl, myristoyl, stearoyl, and polyethylene glycol.

3. The peptide according to claim 1, wherein, The C-terminus of the peptide is bound to an amino group.

4. A cosmetic composition for improving skin condition, comprising a peptide as an active ingredient according to any one of claims 1 to 3.

5. The cosmetic composition according to claim 4, wherein, The peptide was prepared in the form of nanobody.

6. Use of the peptide according to any one of claims 1 to 3 in the preparation of a cosmetic composition for improving skin condition.

7. The use according to claim 6, wherein, The improvement in skin condition is described as wound healing, enhanced skin barrier, or inhibition of skin aging.

8. The use according to claim 6, wherein, The improvement in skin condition refers to the reduction of wrinkles.

9. The use according to claim 6, wherein, The improvement in skin condition refers to improved skin elasticity.

10. The use according to claim 7, wherein, The skin aging mentioned refers to skin aging caused by ultraviolet radiation.

Images